Review

Calpain inhibition as a possible new therapeutic target in multiple sclerosis

  • Received: 04 May 2017 Accepted: 19 October 2017 Published: 26 October 2017
  • Multiple sclerosis (MS), the most common chronic autoimmune inflammatory disease of the central nervous system (CNS), is characterized by demyelination and neurodegeneration. In particular, neurodegeneration is a major factor in disease progression with neuronal death and irreversible axonal damage leading to disability. MS is manageable with current therapies that are directed towards immunomodulation but there are no available therapies for neuroprotection. The complex pathophysiology and heterogeneity of MS indicate that therapeutic agents should be directed to both the inflammatory and neurodegenerative arms of the disease. Activity of the Ca2+ activated protease calpain has been previously implicated in progression of MS and its primary animal model, experimental autoimmune encephalomyelitis (EAE). The effects of calpain inhibitors in EAE involve downregulation of Th1/Th17 inflammatory responses and promotion of regulatory T cells, overall leading to decreased inflammatory cell infiltration in CNS tissues. Furthermore, analysis of brains, spinal cords and optic nerves from EAE animals revealed decreases in axon degeneration, motor neuron and retinal ganglion cell death. This resulted in improved severity of paralysis and preservation of visual function. Taken together, the studies presented in this brief review suggest that use of calpain inhibitors in combination with an immunomodulatory agent may be a potential therapeutic strategy for MS and optic neuritis.

    Citation: Amena W. Smith, Swapan K. Ray, Arabinda Das, Kenkichi Nozaki, Baerbel Rohrer, Naren L. Banik. Calpain inhibition as a possible new therapeutic target in multiple sclerosis[J]. AIMS Molecular Science, 2017, 4(4): 446-462. doi: 10.3934/molsci.2017.4.446

    Related Papers:

    [1] S. J. Gutowska, K. A. Hoffman, K. F. Gurski . The effect of PrEP uptake and adherence on the spread of HIV in the presence of casual and long-term partnerships. Mathematical Biosciences and Engineering, 2022, 19(12): 11903-11934. doi: 10.3934/mbe.2022555
    [2] Sonza Singh, Anne Marie France, Yao-Hsuan Chen, Paul G. Farnham, Alexandra M. Oster, Chaitra Gopalappa . Progression and transmission of HIV (PATH 4.0)-A new agent-based evolving network simulation for modeling HIV transmission clusters. Mathematical Biosciences and Engineering, 2021, 18(3): 2150-2181. doi: 10.3934/mbe.2021109
    [3] Loïc Michel, Cristiana J. Silva, Delfim F. M. Torres . Model-free based control of a HIV/AIDS prevention model. Mathematical Biosciences and Engineering, 2022, 19(1): 759-774. doi: 10.3934/mbe.2022034
    [4] Zindoga Mukandavire, Abba B. Gumel, Winston Garira, Jean Michel Tchuenche . Mathematical analysis of a model for HIV-malaria co-infection. Mathematical Biosciences and Engineering, 2009, 6(2): 333-362. doi: 10.3934/mbe.2009.6.333
    [5] Churni Gupta, Necibe Tuncer, Maia Martcheva . Immuno-epidemiological co-affection model of HIV infection and opioid addiction. Mathematical Biosciences and Engineering, 2022, 19(4): 3636-3672. doi: 10.3934/mbe.2022168
    [6] Romulus Breban, Ian McGowan, Chad Topaz, Elissa J. Schwartz, Peter Anton, Sally Blower . Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. Mathematical Biosciences and Engineering, 2006, 3(3): 459-466. doi: 10.3934/mbe.2006.3.459
    [7] Damilola Olabode, Libin Rong, Xueying Wang . Stochastic investigation of HIV infection and the emergence of drug resistance. Mathematical Biosciences and Engineering, 2022, 19(2): 1174-1194. doi: 10.3934/mbe.2022054
    [8] Esther Chigidi, Edward M. Lungu . HIV model incorporating differential progression for treatment-naive and treatment-experienced infectives. Mathematical Biosciences and Engineering, 2009, 6(3): 427-450. doi: 10.3934/mbe.2009.6.427
    [9] A. M. Elaiw, N. H. AlShamrani . Stability of HTLV/HIV dual infection model with mitosis and latency. Mathematical Biosciences and Engineering, 2021, 18(2): 1077-1120. doi: 10.3934/mbe.2021059
    [10] Oluwaseun Sharomi, Chandra N. Podder, Abba B. Gumel, Baojun Song . Mathematical analysis of the transmission dynamics of HIV/TB coinfection in the presence of treatment. Mathematical Biosciences and Engineering, 2008, 5(1): 145-174. doi: 10.3934/mbe.2008.5.145
  • Multiple sclerosis (MS), the most common chronic autoimmune inflammatory disease of the central nervous system (CNS), is characterized by demyelination and neurodegeneration. In particular, neurodegeneration is a major factor in disease progression with neuronal death and irreversible axonal damage leading to disability. MS is manageable with current therapies that are directed towards immunomodulation but there are no available therapies for neuroprotection. The complex pathophysiology and heterogeneity of MS indicate that therapeutic agents should be directed to both the inflammatory and neurodegenerative arms of the disease. Activity of the Ca2+ activated protease calpain has been previously implicated in progression of MS and its primary animal model, experimental autoimmune encephalomyelitis (EAE). The effects of calpain inhibitors in EAE involve downregulation of Th1/Th17 inflammatory responses and promotion of regulatory T cells, overall leading to decreased inflammatory cell infiltration in CNS tissues. Furthermore, analysis of brains, spinal cords and optic nerves from EAE animals revealed decreases in axon degeneration, motor neuron and retinal ganglion cell death. This resulted in improved severity of paralysis and preservation of visual function. Taken together, the studies presented in this brief review suggest that use of calpain inhibitors in combination with an immunomodulatory agent may be a potential therapeutic strategy for MS and optic neuritis.


    Two seminal HIV prevention policy guidelines were released in 2010: the UNAIDS strategic plan [1] and the United States National HIV/AIDS Strategy (NHAS) [2]. These guidelines precipitated the development of "Getting to Zero" (GTZ) and related HIV elimination initiatives in the United States (US). Following these guidelines, initiatives that focus on HIV elimination within local jurisdictions have been proposed [3]. These plans focus on achieving expanded antiretroviral treatment (ART) and pre-exposure prophylaxis (PrEP) uptake within defined periods. As more ambitious goals are being set to eliminate new HIV infections, the need for improvement at multiple stages of the HIV prevention continuum has been increasingly recognized [4,5]. It is also understood that HIV epidemics in different countries are composed of "microepidemics", driven by disproportionately large numbers of transmissions occurring within some subpopulations [6]. Indeed, data show lower levels of success in the improvement of the ART and PrEP continuums among younger Black gay, bisexual and other MSM (YBMSM) in the US compared with younger white MSM [7,8]. YBMSM have experienced relatively stable incidence rates, even as overall HIV incidence in the United States has declined [9].

    Computational models provide tools to predict the trajectory of localized HIV epidemics, assess the potential effects of interventions, and inform policies for improved implementation of continuums of ART and PrEP care [10,11]. Several computational models demonstrating the potential impact of PrEP, ART and other interventions to promote HIV elimination efforts have been published [12,13,14,15,16]. These models, however, vary in their design, formulation, and input data, and provide predictions that may not always agree [17,18]. Understanding the underlying assumptions of various prediction strategies is important for the interpretation and contextualization of the conflicting findings.

    Applying two or more methodological approaches can help compare the impact of model assumptions on model outputs [19,20,21]. For instance, one can assess the extent to which results from varied approaches are consistent with each other [22] or use data from a variety of sources to examine the range of projected efficacies of prevention mechanisms [23,24]. Studies that compare multiple modeling approaches have been useful in informing HIV prevention policies in Sub Saharan Africa [25,26], but more such studies should be used to guide GTZ planning in the US.

    This paper aims to compare predictions from three different modeling approaches that consider ART and PrEP scale-up among YBMSM in Illinois, a population experiencing an ongoing HIV microepidemic. Two of these approaches are derived from statistical time series techniques and project the number of new HIV infections given recent trends in incidence. A third approach uses stochastic simulations generated from an agent-based network model (ABNM), developed previously, that explicitly simulates person-to-person HIV transmission within sexual networks that were parameterized using empirical data [27]. Results from all three approaches are assessed to determine if a "functional zero" HIV incidence is achieved, defined as fewer than 200 new infections annually [28]. Multi-model comparison approaches such as this may offer a powerful tool for implementation scientists interested in rigorously examining the efficacy of interventions before they are implemented.

    Three approaches are used to project the number of new infections over the 2016-2030 GTZ implementation period [29]. The two statistical approaches use aggregated incidence data obtained through public health surveillance (further information below). These methods are less computationally intensive compared to most dynamic simulation methods used in HIV intervention planning. The third model type described here is an ABNM, described in detail previously [27], that incorporates more of the real-world complexities affecting HIV transmission rates, particularly parameters that describe behavioral, sexual network, demographic, biological, and treatment-related processes.

    All three approaches are used to project HIV incidence among YBMSM over the course of the Illinois GTZ implementation period under the following intervention scenarios: (i) PrEP uptake increased by 20 and 30 percentage points (with no change in ART uptake from the control levels); (ii) ART uptake scaled up by 20 and 30 percentage points (with no change in PrEP uptake from the control levels); (iii) both PrEP and ART scaled up by 20 percentage points each and 30 percentage points each. The increased levels of ART and PrEP use were aligned with the recommended increase in ART and PrEP coverage by the GTZ committee [29]. In addition to the intervention scenarios listed above, a "control" setting assuming baseline uptake levels for PrEP and ART was implemented over the duration of the GTZ implementation. For all interventions, the final outcome was the number of new HIV infections in the last year of GTZ implementation.

    The two statistical approaches used the annual incidences of HIV diagnoses for YBMSM (18-34 years) obtained from the Enhanced HIV/AIDS Reporting System (eHARS), a database maintained by the Illinois Department of Public Health [30]. Baseline PrEP and ART uptake levels were estimated from a population-based cohort study of YBMSM using data collected between June 2013 and July 2016 [31,32]. Input parameters for the ABNM were selected from several different sources which included systematically sampled data representative of YBMSM. Projected numbers of new infections for each year of the GTZ implementation period as per the three interventions considered here were computed using scaling factors, as described in 2.2.1 below. Derivations for the model equations are detailed in the Appendix.

    The Loess technique is a robust local regression technique [33] which optimizes a weighted function that accounts for the closeness of two points in a dataset. The assigned weight is larger if the two points are close to each other and smaller if the points are farther apart. This procedure allows for models to be fit to clusters of data that are close to each other, and specification of a global function that fits all the data is not necessary [33,34,35]. The flexibility that Loess affords in analyzing trend data has led to its use in a number of public health studies, including the incidence of melanoma [36] and celiac disease [37], as well as in projecting the impact of an HPV vaccination program [38]. Besides its flexibility, Loess is also capable of providing residual standard error, allowing the analyst to quantify the uncertainty of predicted values by using the estimated variance of the prediction at that point.

    In the control scenario (where background ART and PrEP does not change), the number of new infections can be projected using the slope parameter which is estimated using existing incidence data. To measure the effect of the various interventions this slope parameter is adjusted by a scaling factor, derived in the Appendix, that accounts for the annual change in ART and PrEP scale-up.

    Recent trends in HIV incidence have been used to model whether the goals of the 2010 US National HIV/AIDS Strategy (NHAS) were achieved and to inform future implementation efforts [39]. This analysis projected US HIV incidence from 2013 to 2015, using observed data on HIV incidence from 2010-2012. This approach is implemented by computing the ratios of observed year-to-year change in HIV incidence using the formula, where the annual change is the ratio of the HIV incidence in year t to the HIV incidence in year (t-1), for the three most recent years for which data are available. In the work introducing this method [39], the mean of the observed incidence ratios from 2010 to 2012 was computed and the incidence for 2013-2015 was projected by multiplying this mean by the HIV incidence in the prior year. Studies have used this approach to call for revisions to policies to reduce HIV incidence [40,41,42,43].

    In the current work, observed HIV incidence ratios for YBMSM in Illinois were computed using data from 2013-2016. HIV incidence for 2017 was computed by multiplying this mean by the observed HIV incidence in 2016. Projected incidences for each of the subsequent years were iteratively computed by considering the mean of the observed incidence ratios for the previous three years.

    An agent-based network model (ABNM) was used to simulate baseline HIV transmission to capture existing epidemic features among BMSM (age 18 to 34 years). The model was populated with 10, 000 individuals at the start of the dynamic simulations. The simulation proceeded in daily time step increments. The substantive model components included arrivals due to agents aging into the model, departures (due to agent mortality or aging out of the model), dynamic sexual network structure, the temporal evolution of CD4 counts and HIV RNA ("viral load"), HIV testing and diagnosis, dynamics of ART and PrEP use, external HIV infections, and HIV transmission dynamics. The ABNM is illustrated in a flow diagram in Figure 1.

    Figure 1.  Flowchart illustrating the various components of the agent-based network model (ABNM). Sexual networks are programmed using the statnet [45] package in the R programming language. All other model components are programmed in the C++-based Repast HPC toolkit [46,47].

    The sexual network structure was modeled using exponential random graph models (ERGMs) [44], a statistically robust approach to model complex network evolution over time, implemented using the statnet [45] suite of packages in the R programming language. The ABM components were developed with the C++-based Repast HPC ABM toolkit [46,47]. Parameters and computer code to reproduce results are available in a public GitHub repository [48]. A full description of these parameters and the process of model calibration has been published previously [27], and the modeling of engagement in the ART and PrEP continuums, as per the intervention scenarios of interest, is described in the Appendix.

    All intervention scenarios and the control were each simulated about 30 times. The primary outcome was the number of new infections per year, averaged across the 30 simulations, along with standard error values calculated over 30 replications at each time point to quantify the uncertainty across the 30 simulations of each scenario (Table 1).

    Table 1.  Projected numbers of new infections among younger Black MSM, ages 18-34 years, in the final year (2030) of Getting to Zero implementation in Illinois. Square brackets show the 1-standard error confidence intervals and the round parentheses show the decline in mean number of infections between the control and the intervention scenarios.
    Loess Bonacci and Holtgravef Agent-based network model
    ControlBaseline ART and PrEP coveragea 383 [349,418] 369 418 [413,422]
    Interventions
    ART coverage only increased by 20%b 362 [308,417] (5%) 181 (51%) 288 [285,292] (31%)
    PrEP coverage only increased by 20%c 367 [317,417] (4%) 202 (45%) 366 [362,369] (12%)
    ART and PrEP coverage increased by 20% 320 [226,414](17%) 99 (73%) 252 [248,256] (40%)
    ART coverage only increased by 30%d 339 [263,415] (12%) 121 (67%) 246 [242,251] (41%)
    PrEP coverage only increased by 30%e 351 [287,416](8%) 145 (61%) 324 [320,329] (22%)
    ART and PrEP coverage increased by 30% 186 [−35, 406](52%) 48 (87%) 186 [184,189] (55%)
    aBaseline ART and PrEP coverage are 50 and 10% respectively
    bART coverage only increased from 50 to 70%
    cPrEP coverage only increased from 10 to 30%
    dART coverage only increased from 50 to 80%
    ePrEP coverage only increased from 10 to 40%
    fBonacci and Holtgrave is a deterministic method and no confidence intervals can be computed.

     | Show Table
    DownLoad: CSV

    The Institutional Review Board of the Biological Sciences Division at The University of Chicago provided approval for the study and waivers of the consent process, where necessary. Appropriate Data User Agreements with the Chicago and Illinois Departments of Public Health for de-identified eHARS data were established.

    The numbers of new infections, projected over the 14 years of GTZ implementation in Illinois, are shown in Figure 2 below. The numbers of new infections in 2030—the last year of GTZ implementation—are given in Table 1. All three models predict somewhat different HIV incidences in the last year of GTZ implementation without any PrEP or ART scale-up. Therefore, the percent decline associated with all three interventions, relative to the infections in the control scenario projected by each approach, is also provided.

    Figure 2.  Projected numbers of new infections among younger Black MSM (ages 18-34) in each year of Getting to Zero implementation in Illinois: (a) Loess, (b) Bonacci and Holtgrave, (c) Agent-based network model under baseline and PrEP and ART scale-up interventions.

    As expected, all three approaches are consistent in predicting that increasing both ART and PrEP by 20% will be more effective in reducing new HIV infections than increasing only one exclusively. The same pattern was observed for the scenarios where a 30% increase was considered. The approaches, however, differ in their predictions of the effectiveness of each intervention. Except for B & H, the other two approaches suggest that a 20% simultaneous PrEP and ART scale-up among YBMSM may not yield a functional zero HIV incidence. The Loess approach predicted the smallest declines, and the B & H showed the largest declines in the cases when ART was scaled up exclusively and when both ART and PrEP were scaled up simultaneously.

    We conclude that a 20% increase in current ART and PrEP coverage levels is unlikely to eliminate new HIV infections among YBMSM in Illinois by the end of the GTZ implementation period. However, all three approaches agree that a 30% scale-up in both ART and PrEP uptake levels may help to reach the GTZ targets by 2030. Of the two statistical time series approaches, B & H projected greater efficacy than Loess. The ABNM, which was based on detailed demographic, behavioral, biological and network parameters, projected an intermediate level of efficacy relative to the two time-series approaches. These differences in results are likely driven by the fundamental assumptions behind the approaches: whereas the projections based on the statistical time series methods are highly dependent on trends in recent incidence, the ABNM incorporates a more granular representation of the processes, and the interactions between these processes.

    Moreover, of the two time series approaches, the B & H method projected a greater decline than the Loess method. This is because the B & H method projects forward "multiplicatively", i.e., by computing the mean of the ratios of the HIV incidence for the past three years and multiplying this ratio by a factor that accounts for the increase in ART and PrEP coverage relative to baseline (Eqs (4) and (5) in the Appendix). The Loess approach, on the other hand, projects forward "linearly", i.e., by considering the slope of the line fitted through the last cluster of points, determined by their closeness, and modifying the slope of this straight line by the increase in ART and PrEP scale-up. The Loess method thus projected minimal change in HIV incidence over 14 years, likely driven by the smaller declines in HIV incidence among YBMSM over recent years. In populations with larger recent declines, Loess would predict greater efficacy of proposed interventions, but using the approach as such might mask important considerations that are specific to populations that are experiencing a disproportionate burden of HIV.

    The finding that ART and PrEP scale-up by 20% points is unlikely to eliminate new HIV infections among YBMSM is, however, consistent across all three approaches. Indeed, previous research has suggested that exclusively scaling up HIV care and treatment would not accomplish NHAS goals [49] and neither would a 20% scale up in PrEP uptake [27]. This conclusion suggests that scale-up of biomedical prevention interventions will need to be intensified among subpopulations where HIV incidence is highest. Some subpopulations where current ART and PrEP scale-up levels have had substantial impact, for instance, may need lower than 20% scale-up. Other subpopulations experiencing higher incidence may require higher than the 20% scale-up currently planned under the GTZ implementation guidelines.

    In scenarios where a 30% scale-up was considered, all three methods show that simultaneous increase in both ART and PrEP uptake levels might help reach GTZ targets, as defined by a functional zero, as described above. Similar to the 20% scale-up level, a 30% increase in ART while keeping PrEP uptake at baseline levels is more effective compared to a 30% increase in PrEP with baseline ART levels.

    Applying multiple methodological approaches allows for an assessment of consistency in the projected findings. The Loess and B & H methods are easier to implement computationally, while the ABNM provides possibilities for a deeper examination of HIV and PrEP continuum variables. Determination of the modeling approach likely depends upon the availability of data and methodological expertise, as well as the projected timelines for modeling findings prior to the implementation of interventions. Our recommended strategy for implementation scientists is to first compute statistical time series type models (for instance, the Loess or B & H, as described in this work), to generate upper and lower bounds of the estimated intervention efficacy. This preliminary work can be followed by longer-term development of more complex ABNM-type models that allow for a more granular examination of specific processes, subpopulations and interventions. The ABNM's primary advantages are that it provides the capacity to incorporate a wider representation of underlying transmission processes, including network mixing, and to examine specific interventions mechanisms explicitly, and investigate how these interventions might impact different population segments.

    Each modeling framework also draws attention to specific contextual considerations. For instance, within Loess and B & H, the uptake of PrEP and ART can be directly controlled, but neither approach has the capacity to model person-to-person transmission explicitly. The impact of ART and PrEP scale-up is realized by considering the multiplicative effects of the number of users at any given time. The ABNM, by contrast, accounted for the HIV care continuum factors that influence ART uptake: testing, linkage, and adherence, but does not provide the flexibility to directly control the number of ART users at any given time. Thus, while the two time-series approaches provided the flexibility of directly controlling an important parameter and were more quickly implemented, the ABNM provided more fine-grained control allowing for explicit examination of key input variables. Identification of a "gold standard" modeling technique is beyond the scope of this study. Rather, this study hopes to compare three modeling frameworks used to project HIV incidence to determine how PrEP and ART scale-up may impact projected HIV incidence. Other modeling approaches, such as deterministic-stochastic modeling choices are available and might be useful in related model comparison studies, depending upon the research questions of interest and the availability of input data [50,51].

    All of the modeling approaches described here use recent data to make projections over 14 years of GTZ implementation. Thus, these models assume that other baseline trends will continue to hold, and the changes that occur will be limited to scale-up of ART and PrEP as per the GTZ strategies considered. Therefore, any structural or policy changes that occur over the GTZ implementation period will not be accounted for in the model. Future model iterations must account for such policies, especially if these policy goals are revised. Computation of all models was based upon approximations about how baseline projections might adapt in response to changes in ART and PrEP coverage. Further work in improving these approximations might be necessary, especially if the resources to develop agent-based simulation models are unavailable. A version of the B & H approach that explicitly allows for a consideration of the 90-90-90 goal to improve engagement the ART continuum has been proposed [52]. A similar version for PrEP scale-up, especially to guide GTZ efforts in the U.S., might be helpful in guiding HIV elimination efforts. Finally, the definition of the functional zero might need to be updated as interventions are rolled out in reality and we approach the later stages of the GTZ planning period.

    Accomplishing GTZ goals will require increased scale-up of ART and PrEP; however, such scale-up may be constrained in part because of the many barriers that prevent effective implementation. Racism, addiction, criminalization, unemployment, lack of access to quality education and health care, and residential segregation are some of the barriers that disproportionately impact young Black men and YBMSM in particular [53,54]. Addressing these barriers is vital to accomplishing HIV elimination goals [55,56]. Indeed, this need to address structural barriers to HIV and PrEP care continuums is recognized in the US [57] and globally [58,59,60,61]. The ABNM provides the flexibility to model interventions that are designed to address these barriers and allows for projected effects of interventions before they are implemented. New modeling approaches that can improve our understanding of the underlying mechanisms by which socio-structural and systemic factors impact HIV transmission and that can quantify the effects of interventions to address them can make a critical contribution to the implementation of interventions [62]. The models described here are being expanded to begin the process of incorporating socio-structural and systemic factors. Next-generation modeling tools can help formulate effective strategies that aid in the design of interventions focused on reducing the impact of these barriers. Triangulation studies allow for increasing amounts of complexity to be examined iteratively in order to make the underlying assumptions behind various approaches more explicit and to derive policy prescriptions that utilize the combined strengths of multiple methodological approaches and data sources.

    The authors acknowledge guidance on implementation science provided by Hendricks Brown and the Center for Prevention Implementation Methodologies (Ce-PIM). This work was completed with computational resources provided by The University of Chicago Research Computing Center. The authors also acknowledge helpful feedback from researchers at the Chicago Center for HIV Elimination. The authors acknowledge input from the BARS Study Group and Getting to Zero IL Research Evaluation and Data (RED) Committee.

    Funding: NIH R03 DA 049662, R01 DA 039934, P30 AI 117943 and P30 DA 027828, and U.S. Department of Energy contract number DE-AC02-06CH11357. The authors acknowledge support from the AIDS Foundation of Chicago and the Pritzker Family Foundation. A.S.K. received partial support from the Providence/Boston Center for AIDS Research (P30AI042853).

    The authors declare that there are no conflicts of interest.

    This Appendix provides additional methodological details of the models described in the main body of the manuscript. Below, model equations for the Loess and Bonacci and Holtgrave (B & H) methods are derived and the modeling of ART and PrEP continuums in the agent-based network model is described.

    The Loess technique is a robust local regression technique [33], which optimizes a weighted function that accounts for the closeness of two points in the dataset. The assigned weight is large if the two points are close to each other and small if the points are farther apart. This procedure allows for models to be fit to clusters of data that are close to each other, and specification of a global function that fits all the data is not necessary [33,34,35].

    A Loess curve was fit to annual incidence data for YBMSM in Illinois, using the loess function in R (version 3.5.3). For any given point, the fitting procedure uses points in the "neighborhood" of that point, defined here as 75% of the points that are closest to it, in accordance with the recommended default value in the R function [63]. These points are weighted by their distance from the point in consideration.

    Incidence data were obtained from the Enhanced HIV/AIDS Reporting System (eHARS), a database maintained by the Illinois Department of Public Health [30]. A slope parameter ρL,t was computed from the fitted values obtained from the last three years (2013–2016), under the assumption that both PrEP and ART were being used in those years, whereas prior to 2013 PrEP was not being used. The projected number of new infections is iteratively computed as

    it+1=it+ρL,t+1 (1)

    where it is the HIV incidence in the "current" year t, and it+1 is the HIV incidence in the following year, t+1. The slope ρL,t+1 is computed as

    ρL,t+1=ρL,tαt+1 (2)

    where α is a factor that scales the slope parameter when ART and PrEP are scaled up. The parameter αt+1 was set to

    (1kAA01kAAt+1)(1kRR01kRRt+1) (3)

    where At is the proportion of HIV-positive individuals using ART in year t, Rt is the proportion of HIV-negative individuals using PrEP in year t. Thus, parameters At and Rt represent ART and PrEP coverage in year t respectively. The parameters A0 and R0 denote ART and PrEP coverage in the first year of the projection, respectively. When ART coverage is scaled up in year t+1, the number of new infections prevented is assumed to be proportional to the relative reduction in the population of the infected individuals, approximated as 1A01At+1.

    Similarly, when PrEP coverage in a given year, Rt, is scaled up, the number of new infections prevented is assumed to be proportional to the population of HIV-negative individuals, approximated as 1R01Rt+1. (Note that when ART and PrEP coverage are not scaled up, A0=A1==At and R0=R1==Rt,, then αt+1 reduces to 1.)

    The factor kA is a weighted average of the protection conferred on individuals who are always, usually, sometimes, and never adherent to ART. From YBMSM cohort data in Illinois, these proportions were estimated to be 32, 28, 30 and 10% respectively [31,32], and the four respective groups was assumed to receive 100, 67, 33 and 0% protection. The factor kR indicates PrEP protection, where data from a PrEP demonstration project were used to estimate that 21.1% of men took 0 pills/week (non-adherent), 7.0% took < 2 pills/week (low adherence), 10.0% took 2–3 pills/week (moderate adherence), and 61.9% took 4+ pills/week (high adherence) [64]. PrEP use is assumed to reduce HIV infection probability in these adherence groups by 0, 31, 81, and 95%, for non, low, moderate, and high adherence, respectively, in accordance with previous modeling work [12]. These protection estimates were assumed to be constant across all models.

    Equation (2) is iteratively solved over the course of the projection period to yield the number of new HIV infections for each projection time point.

    A recent study modeled trends in HIV incidence to assess whether the goals of the 2010 US National HIV/AIDS Strategy (NHAS) were achieved and to inform future implementation efforts [39]. This method is implemented by computing the average of the ratios of observed year-to-year change in HIV incidence using the formula: [annual change = HIV incidence in year t / HIV incidence in year (t-1)] for the three most recent years that data are available for. Thus, the incidence can be iteratively projected as

    it+1=ρBH,tit (4)

    where ρBH,t is the average of the annual change values at the three most recent years as defined above, and it is the HIV incidence in the "current" year t. The number of new infections when ART and PrEP are scaled up is given as

    it+1=ρBH,tit(1kAAt+11kAAt)(1kRRt+11kRRt) (5)

    where parameters are as defined above. Equation (5) is iteratively solved over the course of the projection period to yield the number of new HIV infections for each projection time point.

    An agent-based network model (ABNM) was used to simulate baseline HIV transmission to capture existing epidemic features among adolescents and young adults (age 18 to 34 years). The model was populated with 10, 000 individuals at the start of the dynamic simulations. The simulation proceeded in daily time step increments. The model was calibrated using published HIV incidence and prevalence estimates. A detailed description of the agent-based network model (ABNM) and its parameterization is available elsewhere [27].

    The ABNM is designed to allow for a deeper examination of PrEP and ART care continuums. PrEP uptake was maintained at the base levels by computing a daily initiation probability for HIV-negative individuals not using PrEP. Further, it was assumed that PrEP initiators were retained for an average of one year, consistent with local PrEP continuum data [65]. A dynamic equilibrium was set to balance the PrEP initiation and retention processes to maintain uptake at desired levels. Additionally, PrEP users were divided into four adherence categories, with protection dependent upon adherence. ART uptake, on the other hand, was determined by three care continuum parameters: (a) HIV testing frequency; (b) linkage, defined in the model as distribution of times between HIV diagnosis and ART initiation; (c) ART adherence, modeled by assuming 32, 28, 30, and 10% of ART initiators were always, usually, sometimes, and never adherent, respectively, as estimated from cohort data [31,32].

    The PrEP scale-up intervention was implemented by considering a uniform annual increase from base uptake levels to 30 and 40%. Twenty percent ART scale-up level was modeled by assuming an increase in the proportion of individuals who were always adherent to 80% of ART initiators, and a decline in the proportion of individuals who were usually and sometimes adherent to 10% of ART initiators each. (The impact of increased ART adherence on overall ART uptake is further discussed below.) A similar adherence adjustment approach was used to model the 30% ART scale-up. The six interventions and the baseline scenario were simulated 30 times over the course of the GTZ implementation period to account for inherent uncertainty due to the stochastic nature of this model. In addition, standard error values were also calculated over 30 replications at each time point to quantify the uncertainty (Table 1).

    Since ART uptake in the ABNM was determined by three care continuum parameters described above, the overall uptake was increased by 20% by assuming an increase in the proportion of individuals who were always adherent to 80% of ART initiators, and a decline in the proportion of individuals who were usually and sometimes adherent to 10% of ART initiators each. In the Loess and B & H methods, on the other hand, ART uptake was controlled by specifying the At parameter, as described above. In Figure A1 below, we plot the ART uptake over time in the ABNM, to demonstrate that the increased adherence resulted in a temporal ART scale-up that was comparable to the assumption in the statistical time series methods.

    Figure A1.  Percentage of HIV-positives using antiretroviral treatment under various scenarios of scale-up.
    [1] Dargahi N, Katsara M, Tselios T, et al. (2017) Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci 7: 78. doi: 10.3390/brainsci7070078
    [2] Confavreux C, Vukusic S (2014) The clinical course of multiple sclerosis. Handb Clin Neurol 122: 343-369. doi: 10.1016/B978-0-444-52001-2.00014-5
    [3] Confavreux C, Vukusic S, Moreau T, et al. (2001) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430-1438.
    [4] Kinzel S, Weber MS (2016) B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence. Cns Drug 30: 1137-1148. doi: 10.1007/s40263-016-0396-6
    [5] Fernando NT, Koch M, Rothrock C, et al. (2008) Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14: 1529-1539. doi: 10.1158/1078-0432.CCR-07-4126
    [6] Rottlaender A, Kuerten S. (2015) Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research. Int J Mol Sci 16: 14850-14865.
    [7] Popescu V, Agosta F, Hulst HE, et al. (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosur Psychiatr 84: 1082-1091. doi: 10.1136/jnnp-2012-304094
    [8] Vickers JC, King AE, Woodhouse A, et al. (2009) Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull 80: 217-223. doi: 10.1016/j.brainresbull.2009.08.004
    [9] Mentis AA, Dardiotis E, Grigoriadis N, et al. (2017) Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Mol neurobiol 54: 3911-3923. doi: 10.1007/s12035-017-0530-6
    [10] Berer K, Krishnamoorthy G (2014) Microbial view of central nervous system autoimmunity. FEBS lett 588: 4207-4213. doi: 10.1016/j.febslet.2014.04.007
    [11] Geginat J, Paroni M, Pagani M, et al. (2017) The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance? Trend in Immunol 38: 498-512. doi: 10.1016/j.it.2017.04.006
    [12] Brownlee WJ, Miller DH (2014) Clinically isolated syndromes and the relationship to multiple sclerosis. J Clin Neurosci 21: 2065-2071. doi: 10.1016/j.jocn.2014.02.026
    [13] Rocca MA, Preziosa P, Mesaros S, et al. (2016) Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes-A 2-year MR Imaging Study. Radiology 278: 841-853. doi: 10.1148/radiol.2015150532
    [14] Klaver R, Popescu V, Voorn P, et al. (2015) Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol 74: 453-458. doi: 10.1097/NEN.0000000000000189
    [15] De SN, Giorgio A, Battaglini M, et al. (2010) Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74: 1868-1876. doi: 10.1212/WNL.0b013e3181e24136
    [16] Alonso A, Hernán MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71: 129-135. doi: 10.1212/01.wnl.0000316802.35974.34
    [17] Rojas JI, Patrucco L, Miguez J, et al. (2016) Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact. Arq Neuro-Psiquiat 74: 235-243. doi: 10.1590/0004-282X20160015
    [18] Rojas JI, Patrucco L, Besada C, et al. (2010) [Brain atrophy in clinically isolated syndrome]. Neurología 25: 430-434.
    [19] Tawse KL, Gobuty M, Mendoza-Santiesteban C (2014) Optical coherence tomography shows retinal abnormalities associated with optic nerve disease. Br J Ophthalmol 98: ii30-3. doi: 10.1136/bjophthalmol-2013-304301
    [20] You Y, Gupta VK, Li JC, et al. (2013) Optic neuropathies: characteristic features and mechanisms of retinal ganglion cell loss. Rev Neurosci 24: 301-321.
    [21] Namekata K, Kimura A, Kawamura K, et al. (2013) Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma. Cell Death Diff 20: 1250-1256. doi: 10.1038/cdd.2013.91
    [22] Burkholder BM, Osborne B, Loguidice MJ, et al. (2009) Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol 66: 1366.
    [23] Frohman EM, Dwyer MG, Frohman T, et al. (2009) Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci 282: 96-105. doi: 10.1016/j.jns.2009.04.010
    [24] Pineles SL, Birch EE, Talman LS, et al. (2011) One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol 152: 133-140. doi: 10.1016/j.ajo.2011.01.023
    [25] Martin R, Mcfarland HF, Mcfarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153. doi: 10.1146/annurev.iy.10.040192.001101
    [26] Hobom M, Storch MK, Weissert R, et al. (2004) Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 14: 148-157. doi: 10.1111/j.1750-3639.2004.tb00047.x
    [27] Croxford AL, Kurschus FC, Waisman A (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 1812: 177-183. doi: 10.1016/j.bbadis.2010.06.010
    [28] Shields DC, Banik NL (1999) Pathophysiological role of calpain in experimental demyelination. J Neurosci Res 55: 533-541. doi: 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8
    [29] Hassen GW, Feliberti J, Kesner L, et al. (2006) A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 180: 135-146. doi: 10.1016/j.jneuroim.2006.08.005
    [30] Guyton MK, Das A, Samantaray S, et al. (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88: 2398-2408.
    [31] Kobeissy FH. (2015) Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Crc Press.
    [32] Sun JF, Yang HL, Huang YH, et al. (2017) CaSR and calpain contribute to the ischemia reperfusion injury of spinal cord. Neurosci lett 646: 49-55. doi: 10.1016/j.neulet.2017.03.009
    [33] Samantaray S, Knaryan VH, Shields DC, et al. (2013) Critical role of calpain in spinal cord degeneration in Parkinson's disease. J Neurochem 127: 880. doi: 10.1111/jnc.12374
    [34] Siklos M, Benaissa M, Thatcher GRJ (2015) Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta pharmaceutica Sinica B 5: 506-519.
    [35] Smith AW, Rohrer B, Wheless L, et al. (2016) Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis. J Neurochem 139: 270-284. doi: 10.1111/jnc.13770
    [36] Ono Y, Sorimachi H (2012) Calpains: an elaborate proteolytic system. Biochim Biophys Acta 1824: 224-236. doi: 10.1016/j.bbapap.2011.08.005
    [37] Pietrobon D, Di VF, Pozzan T (1990) Structural and functional aspects of calcium homeostasis in eukaryotic cells. Eur J Biochem 193: 599-622. doi: 10.1111/j.1432-1033.1990.tb19378.x
    [38] Wu HY, Tomizawa K, Matsui H (2007) Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. Acta Medica Okayama 61: 123-137.
    [39] Diaz-Sanchez M, Williams K, Deluca GC, et al. (2006) Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol 111: 289. doi: 10.1007/s00401-006-0045-0
    [40] Yan F, Sun W, Shi Y, et al. (2009) Glutamate excitotoxicity inflicts paranodal myelin splitting and retraction. Plos One 4: e6705. doi: 10.1371/journal.pone.0006705
    [41] Banik NL, Chou CH, Deibler GE, et al. (1994) Peptide bond specificity of calpain: proteolysis of human myelin basic protein. J Neurosci Res 37: 489-496. doi: 10.1002/jnr.490370408
    [42] Howe CL, Lafrancecorey RG, Mirchia K, et al. (2016) Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. Sci Rep 6: 28699. doi: 10.1038/srep28699
    [43] Machado VM, Morte MI, Carreira BP, et al. (2015) Involvement of calpains in adult neurogenesis: implications for stroke. Front Cell Neurosci 9: 22.
    [44] Knaryan VH, Samantaray S, Park S, et al. (2014) SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone. J Neurochem 130: 280-290. doi: 10.1111/jnc.12629
    [45] Donkor IO (2000) A survey of calpain inhibitors. Curr Med Chem 7: 1171-1181. doi: 10.2174/0929867003374129
    [46] Shirasaki Y, Miyashita H, Yamaguchi M, et al. (2005) Exploration of orally available calpain inhibitors: peptidyl alpha-ketoamides containing an amphiphile at P3 site. Bioorg Med Chem 13: 4473-4484. doi: 10.1016/j.bmc.2005.04.059
    [47] Donkor IO, Zheng X, Miller DD (2000) Synthesis and calpain inhibitory activity of alpha-ketoamides with 2,3-methanoleucine stereoisomers at the P2 position. Bioorg Med Chem Lett 10: 2497-2500. doi: 10.1016/S0960-894X(00)00518-7
    [48] Carragher NO (2006) Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Design 12: 615-638. doi: 10.2174/138161206775474314
    [49] Barrett AJ, Kembhavi AA, Brown MA, et al. (1982) L-trans-Epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 201: 189-198. doi: 10.1042/bj2010189
    [50] Saido TC, Sorimachi H, Suzuki K (1994) Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8: 814-822.
    [51] Podbielska M, Das A, Smith AW, et al. (2016) Neuron-microglia interaction induced bi-directional cytotoxicity associated with calpain activation. J Neurochem 139: 440-455. doi: 10.1111/jnc.13774
    [52] Xiao T, Zhang Y, Wang Y, et al. (2013) Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and apoptosis-inducing factor in aldosterone-induced primary cultured cardiomyocytes. Food Chem Toxicol 53: 364-370. doi: 10.1016/j.fct.2012.12.022
    [53] Imai T, Kosuge Y, Endo-Umeda K, et al. (2014) Protective effect of S-allyl-L-cysteine against endoplasmic reticulum stress-induced neuronal death is mediated by inhibition of calpain. Amino Acids 46: 385-393. doi: 10.1007/s00726-013-1628-4
    [54] Li H, Zhang N, Sun G, et al. (2013) Inhibition of the group I mGluRs reduces acute brain damage and improves long-term histological outcomes after photothrombosis-induced ischaemia. ASN Neuro 5: 195.
    [55] Ray SK, Neuberger TJ, Deadwyler G, et al. (2002) Calpain and calpastatin expression in primary oligodendrocyte culture: preferential localization of membrane calpain in cell processes. J Neurosci Res 70: 561-569. doi: 10.1002/jnr.10414
    [56] Das A, Garner DP, Del Re AM, et al. (2006) Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res 1084: 146-157. doi: 10.1016/j.brainres.2006.02.051
    [57] Guyton MK, Brahmachari S, Das A, et al. (2009) Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J Neurochem 110: 1895-1907. doi: 10.1111/j.1471-4159.2009.06287.x
    [58] Guyton MK, Das A, Samantaray S, et al. (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88: 2398-2408.
    [59] Neffe AT, Abell AD (2005) Developments in the design and synthesis of calpain inhibitors. Curr Opin Drug Discov Develop 8: 684-700.
    [60] Das A, Sribnick EA, Wingrave JM, et al. (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 81: 551-562.
    [61] Sharma A1 (2007) Sustained elevation of intracellular cGMP causes oxidative stress triggering calpain-mediated apoptosis in photoreceptor degeneration. Curr Eye Res 32: 259-269. doi: 10.1080/02713680601161238
    [62] Min Y, Zhu W, Zheng X, et al. (2016) Effect of glutamate on lysosomal membrane permeabilization in primary cultured cortical neurons. Mol Med Rep 13: 2499-2505. doi: 10.3892/mmr.2016.4819
    [63] Shirasaki Y, Yamaguchi MH (2006) Retinal penetration of calpain inhibitors in rats after oral administration. J Ocul Pharmacol Ther 22: 417-424. doi: 10.1089/jop.2006.22.417
    [64] Koumura A, Nonaka Y, Hyakkoku K, et al. (2008). A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-met hylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. Neurosci 157: 309-318. doi: 10.1016/j.neuroscience.2008.09.007
    [65] Nakajima E, Hammond KB, Rosales JL, et al. (2011) Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. Invest Ophthalmol Vis Sci 52: 7059-7067. doi: 10.1167/iovs.11-7497
    [66] Trager N, Butler JT, Haque A, et al. (2013) The Involvement of Calpain in CD4+ T Helper Cell Bias in Multple Sclerosis. J Clin Cell Iimmunol 4: 1000153.
    [67] Surh YJ, Chun KS, Cha HH, et al. (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res s480-481: 243-268.
    [68] Potz BA, Sabe AA, Elmadhun NY, et al. (2017) Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. Surgery 161: 1394-1404. doi: 10.1016/j.surg.2016.11.009
    [69] Butler JT, Samantaray S, Beeson CC, et al. (2009) Involvement of calpain in the process of Jurkat T cell chemotaxis. J Neurosci Res 87: 626-635. doi: 10.1002/jnr.21882
    [70] Mikosik A, Jasiulewicz A, Daca A, et al. (2016) Roles of calpain-calpastatin system (CCS) in human T cell activation. Oncotarget 7: 76479-76495.
    [71] Moretti D, Del BB, Allavena G, et al. (2014) Calpains and cancer: friends or enemies? Arch Biochem Biophys 564: 26-36. doi: 10.1016/j.abb.2014.09.018
    [72] Deshpande RV, Goust JM, Hogan EL, et al. (1995) Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res 42: 259-265. doi: 10.1002/jnr.490420214
    [73] Jantzie LL, Winer JL, Corbett CJ, et al. (2016) Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. Dev Neurosci 38: 15-26. doi: 10.1159/000441024
    [74] Guyton MK, Sribnick EA, Ray SK, et al. (2005) A role for calpain in optic neuritis. Ann NY Acad Sci 1053: 48-54. doi: 10.1196/annals.1344.005
    [75] Cerghet M, Skoff RP, Bessert D, et al (2006) Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents. J Neurosci 26: 1439-1447. doi: 10.1523/JNEUROSCI.2219-05.2006
    [76] Ding ZJ, Chen X, Tang XX, et al. (2015) Calpain inhibitor PD150606 attenuates glutamate induced spiral ganglion neuron apoptosis through apoptosis inducing factor pathway in vitro. PLoS One 10: e0123130. doi: 10.1371/journal.pone.0123130
    [77] Das A, Guyton MK, Matzelle DD, et al. (2008) Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis. J Neurosci Res 86: 2992-3001. doi: 10.1002/jnr.21737
    [78] Vosler PS, Brennan CS, Chen J (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 38: 78-100. doi: 10.1007/s12035-008-8036-x
    [79] Schaecher K, Goust JM, Banik NL (2004) The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 29: 1443-1451. doi: 10.1023/B:NERE.0000026410.56000.dd
    [80] Gerondakis S, Grumont R, Rourke I, et al. (1998) The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol 10: 353-359. doi: 10.1016/S0952-7915(98)80175-1
    [81] Miyazaki T, Taketomi Y, Saito Y, et al. (2015) Calpastatin counteracts pathological angiogenesis by inhibiting suppressor of cytokine signaling 3 degradation in vascular endothelial cells. Circ Res 116: 1170-1181. doi: 10.1161/CIRCRESAHA.116.305363
    [82] Datta R, Naura AS, Zerfaoui M, et al. (2011) PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy 66: 853-861. doi: 10.1111/j.1398-9995.2011.02549.x
    [83] Tahvanainen J, Kallonen T, Lähteenmäki H, et al. (2009) PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation. Blood 113: 1268-1277. doi: 10.1182/blood-2008-07-166553
    [84] Hendry L, John S (2004) Regulation of STAT signalling by proteolytic processing. Eur J Biochem 271: 4613-4620. doi: 10.1111/j.1432-1033.2004.04424.x
    [85] Svensson L, Mcdowall A, Giles K M, et al. (2010) Calpain 2 controls turnover of LFA-1 adhesions on migrating T lymphocytes. PLoS One 5: e15090. doi: 10.1371/journal.pone.0015090
    [86] Stewart MP, Mcdowall A, Hogg N (1998) LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J cell Biol 140: 699-707. doi: 10.1083/jcb.140.3.699
    [87] Soede RD, Driessens MH, Ruulsvan SL, et al. (1999) LFA-1 to LFA-1 signals involve zeta-associated protein-70 (ZAP-70) tyrosine kinase: relevance for invasion and migration of a T cell hybridoma. J Immunol 163: 4253-4261.
    [88] Engelhard VH, Altrich-Vanlith M, Ostankovitch M, et al. (2006) Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 18: 92-97. doi: 10.1016/j.coi.2005.11.015
    [89] Imam SA, Guyton MK, Haque A, et al. (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190: 139-145. doi: 10.1016/j.jneuroim.2007.07.016
    [90] Zhang Z, Huang Z, Dai H, et al. (2015) Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury. BioMed Res Int: 134242.
    [91] Posmantur R, Hayes RL, Dixon CE, et al. (1994) Neurofilament 68 and neurofilament 200 protein levels decrease after traumatic brain injury. J Neurotrauma 11: 533-545. doi: 10.1089/neu.1994.11.533
    [92] Zhang JN, Michel U, Lenz C, et al. (2016) Calpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration. Sci Rep 6: 37050. doi: 10.1038/srep37050
    [93] Wilson GN, Smith MA, Inman DM, et al. (2016) Early Cytoskeletal Protein Modifications Precede Overt Structural Degeneration in the DBA/2J Mouse Model of Glaucoma. Front Neurosci 10: 494.
    [94] Saito K, Elce JS, Hamos E, et al. (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90: 2628-2632. doi: 10.1073/pnas.90.7.2628
    [95] Dowling P, Husar W, Menonna J, et al. (1997) Cell death and birth in multiple sclerosis brain. J Neurol Sci 149: 1-11. doi: 10.1016/S0022-510X(97)05213-1
    [96] Gerónimoolvera C, Montiel T, Rinconheredia R, et al. (2017) Autophagy fails to prevent glucose deprivation/glucose reintroduction-induced neuronal death due to calpain-mediated lysosomal dysfunction in cortical neurons. Cell Death Disease 8: e2911. doi: 10.1038/cddis.2017.299
    [97] Sharma AK, Rohrer B (2017) Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J Biol Chem 292: 13186. doi: 10.1074/jbc.A117.401037
    [98] Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70. doi: 10.1038/71555
    [99] Shields DC, Banik NL (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci USA 96: 11486-11491. doi: 10.1073/pnas.96.20.11486
    [100] Zhang ZW, Qin XY, Che FY, et al. (2015) Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats. Genetics and molecular research: GMR 14: 13572-13581. doi: 10.4238/2015.October.28.17
    [101] Kivisäkk P, Mahad DJ, Callahan MK, et al. (2003) Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA 100: 8389-8394. doi: 10.1073/pnas.1433000100
    [102] Lassmann H, Ransohoff RM (2004) The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol 25: 132-137. doi: 10.1016/j.it.2004.01.007
    [103] Dhib S (2003) Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 140: 163-171. doi: 10.1016/S0165-5728(03)00170-X
    [104] Issazadeh S, Mustafa M, Ljungdahl A, et al. (1995) Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 40: 579-590. doi: 10.1002/jnr.490400503
    [105] Kennedy MK, Torrance DS, Picha KS, et al. (1992) Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149: 2496.
    [106] Nishihara M, Ogura H, Ueda N, et al. (2007) IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 19: 695-702. doi: 10.1093/intimm/dxm045
    [107] Immunology N (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132. doi: 10.1038/ni1254
    [108] Park H, Li Z, Yang XO, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141. doi: 10.1038/ni1261
    [109] Passos GRD, Sato DK, Becker J, et al. (2016) Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. Mediat Inflamm 2016: 1-11.
    [110] Zahra S, Rozita D, Masoumeh B, et al. (2016) Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns. PLoS One 11: e0159565. doi: 10.1371/journal.pone.0159565
    [111] Kebir H, Ifergan I, Alvarez JI, et al. (2009) Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 66: 390-402. doi: 10.1002/ana.21748
    [112] Thackray SJ, Mowat CG, Chapman SK (2008) Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans 36: 1120-1123. doi: 10.1042/BST0361120
    [113] Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev 1: 609-620.
    [114] Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154. doi: 10.1172/JCI31178
    [115] Fallarino F, Grohmann U, You S, et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761. doi: 10.4049/jimmunol.176.11.6752
    [116] Mackenzie CR, Heseler K, Müller A, et al. (2007) Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab 8: 237-244. doi: 10.2174/138920007780362518
    [117] Mancuso R, Hernis A, Agostini S, et al. (2015) Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis. Plos One 10: e0130715. doi: 10.1371/journal.pone.0130715
    [118] Sousa DA, Porto WF, Silva MZ, et al. (2016) Influence of Cysteine and Tryptophan Substitution on DNA-Binding Activity on Maize α-Hairpinin Antimicrobial Peptide. Molecules 21: 1062. doi: 10.3390/molecules21081062
    [119] Smith AW, Doonan BP, Tyor WR, et al. (2011) Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol 232: 179-185. doi: 10.1016/j.jneuroim.2010.09.030
    [120] Cilingir V, Batur M, Bulut MD, et al. (2017) The association between retinal nerve fibre layer thickness and corpus callosum index in different clinical subtypes of multiple sclerosis. Neurol Sci 38: 1223-1232. doi: 10.1007/s10072-017-2947-0
    [121] Britze J, Pihljensen G, Frederiksen JL (2017) Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol 264: 1837-1853. doi: 10.1007/s00415-017-8531-y
    [122] Mowry EM, Loguidice MJ, Daniels AB, et al. (2009) Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychia 80: 767-772. doi: 10.1136/jnnp.2008.165449
    [123] Mackay DD (2015) Should patients with optic neuritis be treated with steroids? Curr Opin Ophthalmol 26: 439-444. doi: 10.1097/ICU.0000000000000197
    [124] Dimitriu C, Bach M, Lagrèze WA, et al. (2008) Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. Invest Ophthalmol Vis Sci 49: 5003-5007. doi: 10.1167/iovs.08-1869
    [125] Das A, Guyton MK, Smith A, et al. (2013) Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. J Neurochem 124: 133-143. doi: 10.1111/jnc.12064
    [126] Shields DC, Tyor WR, Deibler GE, et al. (1998) Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. Brain Res 784: 299-304. doi: 10.1016/S0006-8993(97)01381-4
    [127] Hoffmann DB, Williams SK, Jovana B, et al. (2013) Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. J Neuropathol Exp Neurol 72: 745-757. doi: 10.1097/NEN.0b013e31829c7370
    [128] Shimazawa M, Suemori S, Inokuchi Y, et al. (2010) A novel calpain inhibitor, ((1S)-1-((((1S)-1-Benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), reduces murine retinal cell death in vitro and in vivo. J Pharm Exp Ther 332: 380-387. doi: 10.1124/jpet.109.156612
    [129] Imai S, Shimazawa M, Nakanishi T, et al. (2010) Calpain inhibitor protects cells against light-induced retinal degeneration. J Pharm Exp Ther 335: 645-652. doi: 10.1124/jpet.110.171298
    [130] Yokoyama Y, Maruyama K, Yamamoto K, et al. (2014) The role of calpain in an in vivo model of oxidative stress-induced retinal ganglion cell damage. Biochem Biophys Res Comm 451: 510-515. doi: 10.1016/j.bbrc.2014.08.009
    [131] Wang Y, Liu Y, Lopez D, et al. (2017) Protection against TBI-induced neuronal death with post-treatment with a selective calpain-2 inhibitor in mice. J Neurotrauma.
    [132] Tsuda S, Tanaka Y, Kunikata H, et al. (2016) Real-time imaging of RGC death with a cell-impermeable nucleic acid dyeing compound after optic nerve crush in a murine model. Exp Eye Res 146: 179-188. doi: 10.1016/j.exer.2016.03.017
    [133] Ryu M, Yasuda M, Shi D, et al. (2012) Critical role of calpain in axonal damage-induced retinal ganglion cell death. J Neurosci Res 90: 802-815. doi: 10.1002/jnr.22800
    [134] Nemeth CL, Drummond GT, Mishra MK, et al. (2017) Uptake of dendrimer-drug by different cell types in the hippocampus after hypoxic-ischemic insult in neonatal mice: Effects of injury, microglial activation and hypothermia. Nanomedicine 13: 2359-2369. doi: 10.1016/j.nano.2017.06.014
    [135] Zhang F, Trent MJ, Lin YA, et al. (2017) Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model. J Control Release 249: 173-182. doi: 10.1016/j.jconrel.2017.01.032
    [136] Balcer LJ, Galetta SL, Calabresi PA, et al. (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304. doi: 10.1212/01.wnl.0000259521.14704.a8
    [137] Sättler MB, Demmer I, Williams SK, et al. (2006) Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol 201: 172-181. doi: 10.1016/j.expneurol.2006.04.015
    [138] Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6: 889-898. doi: 10.1038/nrn1788
  • This article has been cited by:

    1. Francis Lee, Daniel Sheeler, Anna Hotton, Natascha Del Vecchio, Rey Flores, Kayo Fujimoto, Nina Harawa, John A. Schneider, Aditya S. Khanna, Stimulant use interventions may strengthen ‘Getting to Zero’ HIV elimination initiatives in Illinois: Insights from a modeling study, 2022, 103, 09553959, 103628, 10.1016/j.drugpo.2022.103628
    2. Francis Lee, Aditya S. Khanna, Camden J. Hallmark, Richa Lavingia, Marlene McNeese, Jing Zhao, Melanie L. McNeese, Salma Khuwaja, Babak M. Ardestani, Nicholson Collier, Jonathan Ozik, Anna L. Hotton, Nina T. Harawa, John A. Schneider, Kayo Fujimoto, Expanding Medicaid to Reduce Human Immunodeficiency Virus Transmission in Houston, Texas, 2023, 61, 0025-7079, 12, 10.1097/MLR.0000000000001772
    3. John A. Schneider, Alida Bouris, Ryan White programming that primarily supports clinical care falls short when core people needs are not met: further evidence from the medical monitoring project, 2022, 36, 0269-9370, 1453, 10.1097/QAD.0000000000003233
    4. Adrien Le Guillou, Susan Buchbinder, Hyman Scott, Albert Liu, Diane Havlir, Susan Scheer, Samuel M. Jenness, Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage Among San Francisco Men Who Have Sex With Men, 2021, 88, 1525-4135, 340, 10.1097/QAI.0000000000002781
    5. Shahin Davoudpour, Gregory L. Phillips II, Pedro A. Serrano, Audrey L. French, Sybil G. Hosek, A Memo on Factors Associated with Perception of Stigma Attached to PrEP: Evidence from the Keeping It LITE Study, 2024, 5, 2411-5118, 300, 10.3390/sexes5030023
    6. Mert Edali, Using linear regression metamodels for evaluating interventions in an individual-based influenza epidemic model, 2023, 126, 1569190X, 102772, 10.1016/j.simpat.2023.102772
    7. Heather Mattie, Ravi Goyal, Victor De Gruttola, Jukka-Pekka Onnela, A Review of Network Models for HIV Spread, 2025, 98, 1525-4135, 309, 10.1097/QAI.0000000000003578
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5387) PDF downloads(1045) Cited by(2)

Figures and Tables

Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog